Based in Boston and South San Francisco, precision medicine focused Frontier Medicines, appointed Andy Krivoshik, MD, PhD, to serve as Chief Medical Officer. As Frontier begins its transition into a clinical stage entity focused on generating medicines against disease-causing proteins previously considered undruggable, Dr. Krivoshik will startup, build and lead the drug development team. He…
Category: BIOPHARMACEUTICALS
Chartwell Partners, a national leader in executive search and leadership advisory services, is thrilled to announce that Amy Bottoms has joined us as a Partner in our Biopharmaceuticals practice. With the recent appointments of Amy and Ellen Travers, Chartwell’s Biopharmaceuticals practice adds a wealth of industry specific executive search and inhouse talent acquisition experience across…
Chartwell is delighted to continue our partnership with neurology-focused Xenon Pharmaceuticals, assisting in the recruitment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary. Andrea brings considerable experience helping organizations transition from R&D to commercial stage, most notably during her twelve-year tenure with Biogen and the subsequent spinout of Bioverativ. She served as Executive…
Chartwell Partners is honored to have worked with Protagonist Therapeutics to recruit Arturo Molina, MD, MS, FACP, as Chief Medical Officer. Arturo will be instrumental in guiding the Company’s lead asset, rusfertide, through its global Phase 3 trials, potential regulatory submissions and commercialization. Rusfertide, a mimetic of the natural hormone hepcidin, could transform the treatment…
Chartwell Partners, a national leader in executive search services, announced today that Ellen Travers has joined the firm as a Partner, focused on Board and C-level assignments in our biopharmaceutical and consumer healthcare practices. In her most recent role as the leader of the Talent Acquisition team for Xontogeny, a life science accelerator, Ellen managed…
Chartwell Partners is pleased to announce that Helen Kim has joined Prothena’s Board of Directors. Prothena Corporation plc is a public, late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Ms. Kim has over…
Laurie Hastings joined pediatric CNS focused gene therapy company, Encoded Therapeutics, as Head of People & Culture. Most recently, Laurie served as Vice President and Head of Human Resources for the US affiliate of Vifor Pharma, previously Relypsa, where she led all HR activities for the 220-employee, $120M business. Her earlier career was spent in…
Chartwell Partners is pleased to have worked with public, clinical stage, autoimmune disease focused biopharmaceutical company, Landos Biopharma, to recruit Greg Oakes as President and Chief Executive Officer. Mr. Oakes brings a wealth of experience building and leading organizations through the development and commercialization of life changing medicines. He most recently served as President, North…
Chartwell Partners is pleased to have worked with Chief People Officer, Barbara Howes, to help build the HR team at Eikon Therapeutics, a drug discovery and development company, leveraging its proprietary platform of Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness….
Based in Waltham, MA, Affinia Therapeutics is an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene therapies for rare and prevalent devastating conditions, including next-generation gene therapies for patients with neurologic and neuro-oncologic diseases. AlloVir Chief Executive Officer, Diana Brainard, MD, and retired EY Partner, Carole Faig, were appointed…